STUB

The stock remains in a confirmed Stage 4 decline with sustained lower highs and lower lows under downward-sloping EMAs and no mean-reversion eligibility; medium-term bias is bearish, while short-term timing is neutral—deferring selling until a failed retest at the 9/21 EMA resistance band.

• ↑Reported Q1 2026 net income of $48M and 12% YoY revenue growth to $446M.
• ↑GMS guidance of $9.9–10.1B for FY2026 implies 8–10% growth potential.
• ↓Resale Act imposes 10% price cap, risking ~$95M EBITDA loss if 20% transactions.